Pamicell Signs Supply Contract for Nucleoside Pharmaceutical Intermediate Worth 1.7 Billion KRW
[Asia Economy Reporter Park Jihwan] Pharmicell announced on the 31st that it has signed a supply contract for pharmaceutical intermediate nucleosides with Thermo Fisher Scientific.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
The contract amount is approximately 1.661 billion KRW, which corresponds to 5.11% of last year's sales.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
